Lukas S.
- Country
- Germany
- Department
- Hautklinik - Studienambulanz
Research Overview
- Efficacy and Safety of LAD603 in Adults with Severe to Very Severe Alopecia Areata: A Phase 2, Randomized, Placebo-Controlled Study
- Phase 3 Extension Study of Long-Term Safety and Efficacy of Remibrutinib in Adults With Moderate to Severe Hidradenitis Suppurativa
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Oral Enpatoran in Adults With Active Cutaneous Lupus Erythematosus (with or without systemic disease)
Data & Insights
Has run more than one trial at 126 of 326 partner sites.
Specializations
Inflammatory Skin Disease and Autoimmune Dermatology
Lukas Sollfrank is involved in clinical research on atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, and bullous pemphigoid, with additional interest in cutaneous lupus erythematosus and subacute cutaneous lupus erythematosus.
- Atopic dermatitis
- Psoriasis and psoriatic arthritis
- Hidradenitis suppurativa
- Vitiligo
- Cutaneous lupus erythematosus
His trial portfolio also includes chronic inflammatory dermatoses such as prurigo nodularis, palmoplantar pustulosis, and chronic venous ulcers, reflecting a strong therapeutic focus on immune-mediated skin disease.
Systemic Autoimmune and Rheumatologic Disorders
His research landscape extends to systemic lupus erythematosus, lupus nephritis, systemic sclerosis, rheumatoid arthritis, Sjögren's disease, and idiopathic inflammatory myopathies.
- Systemic lupus erythematosus
- Systemic sclerosis
- Rheumatoid arthritis
- Sjögren's disease
- Idiopathic inflammatory myopathies
He is also engaged in studies of giant cell arteritis, antiphospholipid syndrome, Behçet’s syndrome, and myasthenia gravis, supporting therapeutic development across complex immune-mediated conditions.
Gastroenterology, Hepatology, and Immune-Mediated Intestinal Disease
Lukas Sollfrank is active in trials addressing Crohn's disease, ulcerative colitis, eosinophilic esophagitis, and celiac disease, alongside hepatobiliary conditions such as primary sclerosing cholangitis and primary biliary cholangitis.
- Crohn's disease
- Ulcerative colitis
- Primary sclerosing cholangitis
- Primary biliary cholangitis
- Eosinophilic esophagitis
His clinical interests include therapies for cholestatic pruritus and other inflammatory gastrointestinal disorders, with a clear emphasis on immune-driven disease control.
Oncology and Hematologic Malignancies
His trial involvement spans breast cancer, melanoma, lymphoma, multiple myeloma, acute leukemia, and bladder cancer, including both solid tumors and hematologic cancers.
- Breast cancer
- Melanoma
- Diffuse large B-cell lymphoma
- Multiple myeloma
- Acute lymphoblastic leukemia
He is also involved in research on head and neck squamous cell carcinoma, lung cancer, gastric cancer, and neuroendocrine tumors, indicating broad participation in contemporary oncology innovation.
Neurology, Nephrology, and Other Immune-Mediated Conditions
Lukas Sollfrank’s research activity includes multiple sclerosis, Parkinson’s disease, Alzheimer disease, epilepsy, and status epilepticus, as well as renal and vascular disorders such as chronic kidney disease, IgA nephropathy, and acute kidney injury.
- Multiple sclerosis
- Parkinson’s disease
- Alzheimer disease
- Chronic kidney disease
- IgA nephropathy
His portfolio also covers stroke prevention, heart failure, and obesity, reflecting involvement in therapeutic areas where immune, neurologic, renal, and cardiometabolic disease intersect.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.